IPSWICH, Mass., Aug. 4 /PRNewswire/ -- New England Biolabs is pleased to announce that Canada's Michael Smith Genome Sciences Center has selected New England Biolabs as one of its key suppliers for next-generation sequencing library construction reagents. NEBNext DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited and validated for sample preparation for next generation sequencing, as well as the preparation of expression libraries. Reagents are available for each step of the library construction workflow, and are compatible with the Illumina® GAII and HiSeq2000, Roche/454 GS FLX Titanium™ and LIFE SOLiD™ 4 sequencing platforms. These sets are highly cost effective and each of the components must pass rigorous quality control and functional validation before release.
About New England Biolabs (NEB)
Established in mid 1970s, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis and RNA analysis. Additionally, NEB is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.
About the Michael Smith Genome Sciences Center
The Genome Sciences Centre has a primary mandate to deploy resources and technology of a high-throughput genome mapping and DNA sequencing lab to decrypt the genetic code, specifically to advance cancer research, diagnosis and treatment.
Combining the experience of world-renowned scientists, the GSC plays a major role in the fields of genomics and bioinformatics as well as various genome projects around the world. The priority of the centre is to find innovative means to automate the sequencing and fingerprinting process, develop cost-effective measures that will make such research financially viable and utilize state-of-the-art computing facilities to collect, mine, analyze and disperse data collected at this and other genome facilities.
Illumina is a registered trademark of Illumina, Inc.
GS FLX Titanium is a trademark of Roche.
SOLiD is a trademark of Life Technologies.
|SOURCE New England Biolabs|
Copyright©2010 PR Newswire.
All rights reserved